search
Back to results

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Primary Purpose

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
durvalumab
Doxorubicin-Eluting Beads
TACE
bevacizumab
Tremelimumab
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Cancer focused on measuring Immune Checkpoint Blockade, Combined Treatment, Immunotherapy, Anti-Tumor Immunity, Inhibition of the Blood Vessels Surrounding a Tumor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers
  • INCLUSION CRITERIA:
  • Patients must have:

    • histopathological confirmation of HCC (Cohorts 1 and 3)

OR

  • histopathological confirmation of BTC or histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of BTC (Cohort 2).

    • Patients should have have progressed on standard of care chemotherapy or been intolerant of or refused standard treatment.
    • Patients must have disease that is not amenable to potentially curative resection, radiofrequency ablation, or liver transplantation
    • Patients must have evaluable or measurable disease per RECIST 1.1
    • Patients must have at least one lesion accessible for TACE (Cohort 3)
    • Patients must have lesions accessible for biopsy and be willing to undergo pre- and posttreatment biopsies
    • ECOG performance status of 0 to 1
    • If liver cirrhosis is present, patient must have a Child-Pugh score <7
    • Subjects with HCC must have BCLC C (Cohort 1) or BCLC B (Cohort 3)
    • Patients must have normal organ and marrow function as defined below:
  • absolute neutrophil count greater than or equal to 1,000/mcL
  • platelets greater than or equal to 60,000/mcL
  • total bilirubin:if cirrhosis present: Part of Child Pugh requirement-If no cirrhosis: bilirubin should be less than or equal to 2 XULN
  • ALT or AST up to 5 x ULN
  • Creatinine OR measured or calcutated Creatinine clearance (crCl) (eGFR may Also be used in place of CrCl) A: less than the institutional limit of normal OR greater than or equal to 45/mL/1.73 m^2 for participant with creatinine levels greater than or equal to 1.5 X institutional ULN
  • No proteinuria: Urine dipstick <2. Patients discovered to have greater than or equal to 2 + proteinuria on dipstick analysis should undergo a 24-hour urine collection and must demonstrate less than or equal to 1g of protein in 24 hours to be eligible

    • Age greater than or equal to 18 years
    • Patients must have recovered from any acute toxicity related to prior therapy, including surgery. Toxicity should be less than or equal to grade 1.
    • The effects of study drugs on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) at the study entry and for the duration of study treatment and up to 90 days after the last dose of the study drug(s). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
    • HBV infected subjects must be on antivirals and have HBV DNA <100IU/mL. HCV infected subjects can be enrolled with close HCV RNA level monitoring
    • Body weight >30kg
    • Patient must be able to understand and willing to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Patients who have had standard-of-care anti-cancer therapy or therapy with investigational agents (e.g. chemotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies or other investigation agents) or large field radiotherapy within 4 weeks prior to treatment initiation.
  • Major surgery within 6 weeks prior to treatment initiation. Minor procedures (e.g. port placement, endoscopy with intervention) within 2 weeks prior to treatment initiation.
  • Active central nervous system metastases and/or carcinomatous meningitis. Patients with known active brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses.
  • Medical condition that requires chronic systemic steroid therapy, or any other form of immunosuppressive medication (inhaled and topical steroids are permitted).
  • Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID).
  • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment.
  • Inadequately controlled arterial hypertension (defined as systolic blood pressure (BP) > 150 mmHg and/or diastolic blood pressure > 100 mmHg), based on an average of 3 BP readings on 2 sessions. Note: anti-hypertensive therapy to achieve these parameters is allowable.
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to initiation of study treatment
  • Evidence of bleeding diathesis or significant coagulopathy (with or without current therapeutic anticoagulation).
  • Recent (within 10 days of first dose of study treatment) use of aspirin
  • Thromboembolic event within 6 months of initiation of study treatment (including cerebrovascular accident (CVA) and myocardial infarction (MI).
  • History of hemoptysis (>2.5 mL of bright red blood per episode) within 1 month prior to treatment initiation.
  • Serious, non-healing wound, active ulcer, or untreated bone fracture.
  • HIV-positive patients are excluded because HIV causes complicated immune deficiency and study treatment can pose more risks for these patients.
  • History of severe hypersensitivity reaction to any monoclonal antibody.
  • Congestive heart failure, transmural myocardial infarction, angina pectoris requiring medication, clinically significant valvular disease, high-risk arrhythmia within 12 months prior to treatment initiation. Prior history of hypertensive crisis or hypertensive encephalopathy.
  • Prior invasive malignancies within the past 5 years prior to treatment initiation (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or localized prostate cancer for whom systemic therapy is not required)
  • Active or history of inflammatory bowel disease (colitis, Crohn s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea.
  • History of abdominal fistula or gastrointestinal perforation within 6 months prior to initiation of study treatment.
  • History of chronic autoimmune disease (e.g., Addison s disease, multiple sclerosis, Graves disease, Hashimoto s thyroiditis, rheumatoid arthritis, hypophysitis, systemic lupus erythematosus, Wegener s granulomatosis, sarcoidosis syndrome etc.) or other connective tissue diseases with symptomatic disease within the 3 years of initiation of study treatment. Note: Active vitiligo or a history of vitiligo will not be a basis for exclusion.
  • Diverticulitis either active or history of within 2 years of initiation of study treatment. Note that diverticulosis is permitted.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that may impair the patient s tolerance of study treatments.
  • Received any live vaccine within the last 30 days before treatment initiation.
  • Patients who have undergone prior liver transplantation.
  • Pregnant women are excluded from this study because durvalumab s and bevacizumab s potential for teratogenic or abortifacient effects is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tremelimumab, durvalumab and bevacizumab, breastfeeding should be discontinued if the mother is treated with study drugs.

Sites / Locations

  • National Institutes of Health Clinical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

1/Arm 1

2/Arm 2

Arm Description

Durvalumab, bevacizumab and tremelimumab

Durvalumab, bevacizumab, tremelimumab and TACE

Outcomes

Primary Outcome Measures

To evaluate the 6-month progression free survival (PFS) in patients with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE
Proportion of patients with advanced HCC BCLC stage B that have progressive disease after 6 months
To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab
Proportion of patients with BTC and HCC BCLC stage C that have progressive disease after 6 months

Secondary Outcome Measures

To determine the best overall response (BOR) rate according to Response Evaluation Criteria (RECIST 1.1) in patients with advanced HCC and BTC
Proportion of patients whose tumors shrunk after therapy
To characterize overall survival (OS) in patients with advanced HCC and BTC treated on this study
Median amount of time subject survives after therapy
To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab and TACE in patients with advanced HCC
List of adverse event type, grade and frequency
To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab in patients with advanced BTC
List of adverse event type, grade and frequency

Full Information

First Posted
May 3, 2019
Last Updated
July 25, 2023
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT03937830
Brief Title
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Official Title
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Study Type
Interventional

2. Study Status

Record Verification Date
July 21, 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 10, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months. Researchers are evaluating a combination of treatment drugs to delay the progression of HCC; aiming to help people with HCC live longer. Objective: To study the 6-month progression-free survival in people with advanced HCC treated with bevacizumab, durvalumab, and TACE. Eligibility: Adults ages 18 and older with intermediate or advanced HCC Design: Participants will be screened with a physical exam and medical history. They will have tests to evaluate their hearts as well as blood and urine. A CT and/or MRI scans will be done during the study. If a prior tumor sample is not available; participants may undergo a biopsy. They may undergo an endoscopy of their esophagus and stomach. Participants will get the study drugs in 21-day cycles: Two treatment drugs will be injected into a vein every 3 weeks. Patients will have an interventional treatment procedure done by interventional radiology under sedation; chemotherapy beads will be infused into artery branches in the liver. Participants may have to stay in the hospital for 24 hours for observation, after this procedure. This interventional procedure may be done more than once during the study. Participants may need to repeat some of the screening tests throughout the study. Participants may have to stop taking some of their cancer treatment drugs during the study. Participants will continue on the study until their cancer progresses or until the side effects of the treatment drugs are not tolerable....
Detailed Description
Background: Worldwide, hepatocellular carcinoma (HCC) is the fourth most common cause of cancer related death with a median survival of 6-9 months. Biliary tract carcinoma (BTC) is relatively uncommon and includes cancers of the gallbladder and intra- and extra-hepatic biliary ductal system, although periampullary tumors are often considered part of this group as well. A class of agents that in the recent years has been at the epicenter of immunotherapy approaches in gastrointestinal malignancies are the monoclonal antibodies (mAbs) against the immune checkpoint inhibitors CTLA4, PD-1 and PD-L1. Durvalumab is a human monoclonal antibody of the immunoglobulin G1 kappa (IgG1k ) subclass. Durvalumab inhibits binding of programmed cell death ligand 1 (PD-L1) to programmed cell death 1 (PD-1) and CD80. Anti-PD-L1 antibodies directly target tumor cells and are expected to have less adverse events in comparison with anti-PD-1 antibodies that target effector T-cells in the tumor microenvironment. Tremelimumab is a human IgG2 mAb directed against CTLA-4. Tremelimumab blocks the inhibitory effect of CTLA-4, and therefore enhances T cell activation. Angiogenesis is defined as the formation of new blood capillaries, which is a complex process that promotes vascular endothelial growth factor (VEGF) and other proangiogenic factor expression, thus enhancing metastasis. Inhibition of VEGF function by bevacizumab can lead to the inhibition of the new blood vessels formation surrounding a tumor, and consequently arrest the tumor growth by depriving essential nutrients and oxygen. TACE has been shown to induce anti-tumor immunity. Early phase studies have shown that anti-VEGF treatment with bevacizumab in combination with TACE decreases neovascular formation. We have previously shown that locoregional therapies can be safely combined with immune checkpoint blockade. There are also preclinical data suggesting that anti-VEGF therapy may target myeloid cells with suppressor activity. Objectives: To evaluate the 6-month progression free survival (PFS) in patients with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE. To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab. Eligibility: Histopathological confirmation of HCC or BTC or histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of BTC. Patients must have evaluable or measurable disease per RECIST 1.1. Patients must have disease that is not amenable to potentially curative resection, radiofrequency ablation, or liver transplantation. Design: This is an open label Phase II trial conducted to evaluate efficacy of durvalumab, bevacizumab and tremelimumab combined treatment in patients with advanced HCC BCLC stage C or BTC and efficacy of durvalumab, bevacizumab, tremelimumab and TACE combined treatment in patients with advanced HCC BCLC stage B. Initially 3-18 patients with HCC BCLC Stage C or BTC will be enrolled into safety run-in of Arm 1 to determine the safety of combined treatment of durvalumab, bevacizumab and tremelimumab. Once safety has been determined, subsequent patients with HCC BCLC Stage C and BTC will be enrolled in Arm 1 and patients with HCC BCLC Stage B will start enrollment into Arm 2, consistent of durvalumab, bevacizumab, tremelimumab and multiple TACE procedures. Treatment will continue until progression or unbearable toxicity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Keywords
Immune Checkpoint Blockade, Combined Treatment, Immunotherapy, Anti-Tumor Immunity, Inhibition of the Blood Vessels Surrounding a Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
39 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1/Arm 1
Arm Type
Experimental
Arm Description
Durvalumab, bevacizumab and tremelimumab
Arm Title
2/Arm 2
Arm Type
Experimental
Arm Description
Durvalumab, bevacizumab, tremelimumab and TACE
Intervention Type
Drug
Intervention Name(s)
durvalumab
Intervention Description
1,150 mg flat dose every 21 days, starting on day 1 of cycle 1
Intervention Type
Drug
Intervention Name(s)
Doxorubicin-Eluting Beads
Intervention Description
used for TACE (only in patients with HCC BCLC stage B)
Intervention Type
Procedure
Intervention Name(s)
TACE
Intervention Description
TACE with Doxorubicin-Eluting Beads (only in patients with HCC BCLC stage B) on Cycle 2. More TACE can be done if clinically necessary.
Intervention Type
Drug
Intervention Name(s)
bevacizumab
Intervention Description
7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2
Intervention Type
Drug
Intervention Name(s)
Tremelimumab
Intervention Description
300, 150 or 75 mg once on day 1 of cycle 1
Primary Outcome Measure Information:
Title
To evaluate the 6-month progression free survival (PFS) in patients with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE
Description
Proportion of patients with advanced HCC BCLC stage B that have progressive disease after 6 months
Time Frame
6 months
Title
To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab
Description
Proportion of patients with BTC and HCC BCLC stage C that have progressive disease after 6 months
Time Frame
6 months
Secondary Outcome Measure Information:
Title
To determine the best overall response (BOR) rate according to Response Evaluation Criteria (RECIST 1.1) in patients with advanced HCC and BTC
Description
Proportion of patients whose tumors shrunk after therapy
Time Frame
every 9 weeks
Title
To characterize overall survival (OS) in patients with advanced HCC and BTC treated on this study
Description
Median amount of time subject survives after therapy
Time Frame
death
Title
To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab and TACE in patients with advanced HCC
Description
List of adverse event type, grade and frequency
Time Frame
every visit to clinical center
Title
To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab in patients with advanced BTC
Description
List of adverse event type, grade and frequency
Time Frame
every visit to clinical center

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Patients must have: histopathological confirmation of HCC (Cohorts 1 and 3) OR histopathological confirmation of BTC or histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of BTC (Cohort 2). Patients should have have progressed on standard of care chemotherapy or been intolerant of or refused standard treatment. Patients must have disease that is not amenable to potentially curative resection, radiofrequency ablation, or liver transplantation Patients must have evaluable or measurable disease per RECIST 1.1 Patients must have at least one lesion accessible for TACE (Cohort 3) Patients must have lesions accessible for biopsy and be willing to undergo pre- and posttreatment biopsies ECOG performance status of 0 to 1 If liver cirrhosis is present, patient must have a Child-Pugh score <7 Subjects with HCC must have BCLC C (Cohort 1) or BCLC B (Cohort 3) Patients must have normal organ and marrow function as defined below: absolute neutrophil count greater than or equal to 1,000/mcL platelets greater than or equal to 60,000/mcL total bilirubin:if cirrhosis present: Part of Child Pugh requirement-If no cirrhosis: bilirubin should be less than or equal to 2 XULN ALT or AST up to 5 x ULN Creatinine OR measured or calcutated Creatinine clearance (crCl) (eGFR may Also be used in place of CrCl) A: less than the institutional limit of normal OR greater than or equal to 45/mL/1.73 m^2 for participant with creatinine levels greater than or equal to 1.5 X institutional ULN No proteinuria: Urine dipstick <2. Patients discovered to have greater than or equal to 2 + proteinuria on dipstick analysis should undergo a 24-hour urine collection and must demonstrate less than or equal to 1g of protein in 24 hours to be eligible Age greater than or equal to 18 years Patients must have recovered from any acute toxicity related to prior therapy, including surgery. Toxicity should be less than or equal to grade 1. The effects of study drugs on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) at the study entry and for the duration of study treatment and up to 90 days after the last dose of the study drug(s). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. HBV infected subjects must be on antivirals and have HBV DNA <100IU/mL. HCV infected subjects can be enrolled with close HCV RNA level monitoring Body weight >30kg Patient must be able to understand and willing to sign a written informed consent document. EXCLUSION CRITERIA: Patients who have had standard-of-care anti-cancer therapy or therapy with investigational agents (e.g. chemotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies or other investigation agents) or large field radiotherapy within 4 weeks prior to treatment initiation. Major surgery within 6 weeks prior to treatment initiation. Minor procedures (e.g. port placement, endoscopy with intervention) within 2 weeks prior to treatment initiation. Active central nervous system metastases and/or carcinomatous meningitis. Patients with known active brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses. Medical condition that requires chronic systemic steroid therapy, or any other form of immunosuppressive medication (inhaled and topical steroids are permitted). Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID). A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment. Inadequately controlled arterial hypertension (defined as systolic blood pressure (BP) > 150 mmHg and/or diastolic blood pressure > 100 mmHg), based on an average of 3 BP readings on 2 sessions. Note: anti-hypertensive therapy to achieve these parameters is allowable. Prior history of hypertensive crisis or hypertensive encephalopathy Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to initiation of study treatment Evidence of bleeding diathesis or significant coagulopathy (with or without current therapeutic anticoagulation). Recent (within 10 days of first dose of study treatment) use of aspirin Thromboembolic event within 6 months of initiation of study treatment (including cerebrovascular accident (CVA) and myocardial infarction (MI). History of hemoptysis (>2.5 mL of bright red blood per episode) within 1 month prior to treatment initiation. Serious, non-healing wound, active ulcer, or untreated bone fracture. HIV-positive patients are excluded because HIV causes complicated immune deficiency and study treatment can pose more risks for these patients. History of severe hypersensitivity reaction to any monoclonal antibody. Congestive heart failure, transmural myocardial infarction, angina pectoris requiring medication, clinically significant valvular disease, high-risk arrhythmia within 12 months prior to treatment initiation. Prior history of hypertensive crisis or hypertensive encephalopathy. Prior invasive malignancies within the past 5 years prior to treatment initiation (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or localized prostate cancer for whom systemic therapy is not required) Active or history of inflammatory bowel disease (colitis, Crohn s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea. History of abdominal fistula or gastrointestinal perforation within 6 months prior to initiation of study treatment. History of chronic autoimmune disease (e.g., Addison s disease, multiple sclerosis, Graves disease, Hashimoto s thyroiditis, rheumatoid arthritis, hypophysitis, systemic lupus erythematosus, Wegener s granulomatosis, sarcoidosis syndrome etc.) or other connective tissue diseases with symptomatic disease within the 3 years of initiation of study treatment. Note: Active vitiligo or a history of vitiligo will not be a basis for exclusion. Diverticulitis either active or history of within 2 years of initiation of study treatment. Note that diverticulosis is permitted. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that may impair the patient s tolerance of study treatments. Received any live vaccine within the last 30 days before treatment initiation. Patients who have undergone prior liver transplantation. Pregnant women are excluded from this study because durvalumab s and bevacizumab s potential for teratogenic or abortifacient effects is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tremelimumab, durvalumab and bevacizumab, breastfeeding should be discontinued if the mother is treated with study drugs.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Donna M Hrones, C.R.N.P.
Phone
(240) 858-3155
Email
donna.mabry@nih.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Tim F Greten, M.D.
Phone
(240) 760-6114
Email
gretentf@mail.nih.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tim F Greten, M.D.
Organizational Affiliation
National Cancer Institute (NCI)
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institutes of Health Clinical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
Phone
888-624-1937

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
.All IPD recorded in the medical record will be shared with intramural investigators upon request.@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP
IPD Sharing Time Frame
Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
IPD Sharing Access Criteria
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.
Links:
URL
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2019-C-0094.html
Description
NIH Clinical Center Detailed Web Page

Learn more about this trial

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

We'll reach out to this number within 24 hrs